Overview of CRISPR
CRISPR is an innovative instrument that is revolutionizing lives and making significant impacts in the healthcare sector. CRISPR, which denotes “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—minute, unicellular entities devoid of organelles. These sequences are situated within the genomes of prokaryotes, which package a cell’s DNA in clusters.
Functioning as a gene editing mechanism, CRISPR is utilized to alter particular areas of DNA to address critical health issues. Its effectiveness lies in its capability to shield the body from viral attacks by integrating the foreign DNA into its own genome, thus enabling it to identify and eradicate the virus in subsequent encounters. Notably, in comparison to alternative gene editing techniques, CRISPR demonstrates superior precision and simplicity in programming, facilitating an easier redesigning of sequences. While many gene-editing methods depend on a single protein, CRISPR utilizes RNA-guided targeting in conjunction with the Cas9 enzyme.
Mechanism of CRISPR
CRISPR operates by employing a natural defense system found in bacteria that enables them to detect and eliminate viral threats. When a virus infiltrates a bacterial cell (a prokaryote), the bacterium retains a piece of the invader’s DNA within its genome as a genetic “remembrance.” This allows the bacterium to identify and react more efficiently to later infections.
In gene editing, this mechanism is modified with two primary elements: the Cas9 enzyme, which acts like molecular scissors to cleave DNA, and guide RNA, which directs Cas9 to the particular genetic sequence needing modification. After the desired DNA is severed, the cell’s inherent repair processes take charge, allowing researchers to implement alterations to the genetic material.
Differing from previous tools that depended on difficult-to-reprogram proteins, CRISPR’s RNA-guided approach is more adaptable, simpler to design, and remarkably precise. This ease and accuracy have enabled CRISPR’s application in healthcare, agriculture, production, and microbiology—such as engineering microorganisms to boost product yields. Nevertheless, as discussed in this article, the expansion of these capabilities brings about increasing ethical dilemmas, particularly concerning germline editing and genetic enhancement.
First Patient of a Customized CRISPR Treatment
In February 2025, the inaugural customized CRISPR treatment was administered to an infant named KJ to address a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—a critical enzyme responsible for converting ammonia (produced during protein breakdown) into urea. A research team led by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia developed this therapy after extensive research in gene editing and collaboration with other medical professionals.
Their research focused on conditions that disrupt the urea cycle, leading to hazardous ammonia accumulation, which can damage organs such as the brain and liver. They customized the treatment specifically for KJ’s type of CPS1 deficiency using preclinical studies on similar variants.
Until now, the only CRISPR therapies authorized by the U.S. FDA were for more prevalent diseases such as sickle cell disease and beta thalassemia, impacting tens or hundreds of thousands of individuals. In KJ’s situation, his treatment was devised within six months of his birth, focusing on his unique CPS1 variant. The team developed a base editing therapy administered through lipid nanoparticles to his liver to rectify the defective enzyme.
The February treatment marked the first of three doses; KJ received the subsequent two in March and April 2025. As of his final dose, he has not experienced any severe side effects, displays enhanced tolerance to dietary protein, and necessitates less medication to regulate ammonia levels. Though he will require continuous monitoring, Ahrens-Nicklas reports that the results thus far are encouraging.
CRISPR Ethical Issues
As with any pioneering technology, CRISPR prompts intricate ethical inquiries. While its main intent is to edit somatic cells for disease treatment, it can also be utilized on gametes, veering into the contentious domain of germline editing. Modifying DNA that will be passed on to future generations often